During the trial, patients took dostarlimab every three weeks for six months. Remarkably, they were all in the same stage of their cancer. The cancer had developed locally in the rectum but had not spread to other organs.
For the first time, the effectiveness of a womb cancer drug undergoing clinical trials has surprised everyone. The drug, dostarlimab, has cured every participant in the trial. A small group of people with colon cancer saw their cancer disappear after experimental treatment. According to reports, 18 patients in a small clinical trial took Dostarlimab for about six months and after more than 12 months doctors found that their cancer had disappeared.
According to experts, Dostarlimab is a drug with lab-made molecules and it acts as a substitute antibody in the human body. Reportedly, all 18 rectal cancer patients were given the same drug and as a result of the treatment, the cancer was completely eradicated in each patient. Cancer cannot be detected by physical examination; endoscopy; Positron emission tomography or PET scan or MRI scan.
Although the trial sample size is quite small, it certainly proves that dostarlimab may be a potential cure for one of the most deadly common cancers. Dr. Louis A. of Memorial Sloan Kettering Cancer Center in New York. Diaz J. Said it was “the first time in the history of cancer”.
According to reports, the patients included in the clinical trial previously underwent treatments such as chemotherapy, radiation and invasive surgery, which can result in bowel, urinary and even sexual dysfunction. In addition, 18 patients went into the trial hoping to undergo these as a next step. However, to their surprise, no further treatment was required.
The findings of this trial have shocked experts around the world and experts have pointed out that complete remission is “unheard of” in every patient.
Many experts have hailed the research as world-first and highlighted that it is more impressive because not all patients suffered significant complications from the trial drug. Meanwhile, oncologist Dr Andrea Cersek, a co-author of the paper, described the moment the patients found out they were cancer-free.
During the trial, patients took dostarlimab every three weeks for six months. Remarkably, they were all in the same stage of their cancer. The cancer had developed locally in the rectum but had not spread to other organs.
At the time of this report, none of the patients had undergone chemoradiotherapy or surgery, and no cases of progression or recurrence were reported during follow-up, the researchers wrote in the study published Sunday in the New England Journal of Medicine.
Scientists have said the treatment looks promising, however, that large-scale trials are needed to see if it will work for more patients and whether the cancer is truly in remission.